OmniAb, Inc. OABI 深 滬
等待開盤 07-31 09:30:00 美东时间
1.99
+0.040
+2.05%
華盛通- 最 高2.019
- 今 開1.95
- 成交量 20.42万股
- 最 低 1.95
- 昨 收 1.95
- 總市值 2.88亿
- 52周最高 2.79
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 1.30
- 委 比 72.54%
- 總股本 1.45亿
- 歷史最高 10.87
- 量 比 0.70
- 振 幅 3.54%
- 歷史最低 1.22
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
Austin, Texas, United States, July 27th, 2026, FinanceWire VERAXA Biotech (NASD...
07-28 02:30
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", ))), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc. (NASDAQ...
07-27 19:07
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech AG and OmniAb, Inc. announce the advancement of their bispecific ADC (bsADC) program VXA-222, utilizing an "AND-gate" logic to target two solid tumor antigens. Following successful completion of OmniAb's discovery work, the program enters its next phase, combining OmniAb's antibody solutions with VERAXA's ADC linker technology. VERAXA will develop and validate the lead candidate, with exclusive rights to commercialize products inco...
07-27 11:00
OmniAb Names Amechi Nwachuku Chief Operating Officer
The latest update is out from OmniAb ( ($OABI) ). Effective July 13, 2026, Omni...
07-13 20:48
VERAXA Biotech Channels Investment Into BiTAC Portfolio, Eyes BiTAC-TCE Candidate VXA-102 IND/CTA-Ready By 2028
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. "In the first six months of 2026, we have made substantial progress in honing our pipeline and partnering strategy. We continue to record tangible intere...
07-06 19:12
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
VERAXA Biotech AG has made significant progress in its BiTAC® platform for developing conditionally active T cell engagers and antibody-drug conjugates. The company plans to prioritize investments in BiTAC-based therapies, aiming to advance VXA-102 to IND/CTA readiness by early 2028. With four BiTAC programs targeting solid tumors and two bispecific ADCs, VERAXA is leveraging its differentiated technology to attract partnerships, especially follo...
07-06 11:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 147.2% to ...
05-20 20:06
OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook
Earnings Call Insights: OmniAb, Inc. (OABI) Q1 2026 Management view "OmniAb delivered a very strong start to the year, largely driven by advancement of our partner programs," said President, CEO & Dir...
05-08 11:02
电话会总结 ｜ OmniAb(OABI)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据OmniAb业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2025年全年营收为1,870万美元，较2024年的2,640万美元下降29.2%。营收下降主要由于许可费和里程碑付款收入减少，但部分被Exploration平台带来的80万美元收入所抵消。 **盈利状况：** 2025年净亏损为6,480万美元（每股亏损0.57美元），较2024年净亏损6,200万美元（每股亏损0.61美元）略有扩大。如扣除第四季度390万美元的非现金减值费用，每股亏损将为0.54美元。 **运营费用：** 2025年运营费用为8,76
03-16 14:08
